J.P. Morgan Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report). The company’s shares closed yesterday at $2.98.

Vatnsdal covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Agilent, and Bruker. According to TipRanks, Vatnsdal has an average return of -4.7% and a 42.39% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptive Biotechnologies with a $6.60 average price target.

ADPT market cap is currently $451.2M and has a P/E ratio of -1.99.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADPT in relation to earlier this year. Last month, Peter Neupert, a Director at ADPT bought 15,000.00 shares for a total of $12,600.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adaptive Biotechnologies (ADPT) Company Description:

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.